| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP, Corp and Development Ops | Vice President Level 14
1 company
Brian Birchler is EVP, Corp and Development Ops at IONS. Brian Birchler's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $4.2M at current prices.
Our model assigns Brian Birchler a middling insider score of 65/100, based on 11 past trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of +5.9%.
The IONS filings lean toward selling, a net 59,686 shares.
Brian Birchler has 21 Form 4 filings on record from April 2023 to August 2026, all as EVP, Corp and Development Ops at Ionis Pharmaceuticals (IONS), 2023–2026.
The 38 reported transactions were 11 open-market sales, 10 option exercises, 9 option or other derivative awards and 6 other transactions, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 10 sales worth about $4.0M.
The largest open-market sale was 23,900 shares of IONS at an average $72.13 on October 15, 2025, about $1.7M. Twelve months later IONS was down 39%.
2 of the 10 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 8 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 16, 2026 | IONS Ionis Pharmaceuticals, Inc. | EVP, Corp and Development Ops | Sale+OE | 973 | $75.04 | $73,015.87 | -1.4% | -27.3% | - | |
| Jan 30, 2026 | IONS Ionis Pharmaceuticals Inc | EVP, Corp and Development Ops | Sell | 6,179 | $83.03 | $513,047.93 | -8.5% | -9.6% | - | |
| Jan 16, 2026 | IONS Ionis Pharmaceuticals, Inc. | EVP, Corp and Development Ops | Sale+OE | 8,480 | $75.11 | $636,932.80 | -12.3% | -1.4% | - | |
| Nov 6, 2025 | IONS Ionis Pharmaceuticals Inc | EVP, Corp and Development Ops | Sell10b5-1 | 8,000 | $76.17 | $609,379.20 | -14.1% | +14.7% | - | |
| Oct 15, 2025 | IONS Ionis Pharmaceuticals Inc | EVP, Corp and Development Ops | Sale+OE10b5-1 | 23,900 | $72.13 | $1,723,987.11 | -29.6% | +9.8% | -39.1% | |
| Apr 16, 2025 | IONS Ionis Pharmaceuticals Inc | EVP, Corp and Development Ops | Sale+OE | 680 | $28.37 | $19,291.60 | -1.2% | +48.1% | - | |
| Jan 16, 2025 | IONS Ionis Pharmaceuticals Inc | EVP, Corp and Development Ops | Sale+OE | 5,400 | $32.70 | $176,580.00 | -8.9% | -12.2% | +136.5% | |
| Apr 16, 2024 | IONS Ionis Pharmaceuticals Inc | EVP, Corp and Development Ops | Sale+OE | 905 | $41.66 | $37,698.23 | -1.9% | +14.5% | -31.8% | |
| Jan 17, 2024 | IONS Ionis Pharmaceuticals Inc | EVP, Corp and Development Ops | Sale+OE | 4,497 | $50.42 | $226,725.25 | -9.2% | -19.0% | -37.1% | |
| Apr 18, 2023 | IONS Ionis Pharmaceuticals Inc | EVP, Corp and Development Ops | Sale+OE | 672 | $36.50 | $24,529.61 | -1.8% | +16.0% | +12.5% |